健倍苗苗(02161.HK)擬1.71億港元收購天喜堂藥廠90%股權
格隆匯2月21日丨健倍苗苗(02161.HK)公告,於2025年2月21日,買方(公司的間接全資附屬公司)與賣方訂立買賣協議,據此,買方有條件同意收購而賣方有條件同意出售銷售股份(佔目標公司天喜堂藥廠有限公司已發行股本的90%),根據買賣協議的條款及條件,總代價爲1.71億港元。
目標公司爲於香港註冊成立的有限公司,主要從事製造、推廣及銷售品牌中藥天喜堂天喜丸。天喜堂天喜丸擁有悠久歷史傳承,在香港及中國內地(特別是廣東省)享有極高的品牌知名度。其配方專爲調節女性生理週期、促進生殖健康及增強血液循環以展現紅潤氣色而設,深受女性消費者信賴,被廣泛視爲婦科健康的可靠良方。集團認爲,天喜堂天喜丸是一個極具價值的優質品牌,爲集團的長遠業務增長帶來重要的戰略價值。
收購事項爲集團提供了一個寶貴的機會,以擴展其品牌中藥組合,並加速其增長策略。通過將這一標誌性品牌納入現有的傳統中藥產品組合,集團可充分把握市場增長機遇,迎合消費者對全人健康解決方案日益增長的需求。集團深信,收購事項將帶來可持續的銷售增長,併產生穩健的現金流和盈利增幅。
爲了充分發揮品牌潛力,集團計劃開展全面的市場推廣活動,憑藉其成熟的品牌管理專長,提升品牌知名度並加強消費者互動。通過擴展分銷網絡及市場覆蓋範圍,集團將致力挖掘天喜堂天喜丸的潛力,拓展未被充分開發的市場,並吸引新的客戶羣。這些舉措預期將推動銷售與盈利表現,從而爲集團創造重要的戰略價值。
此外,收購事項預期可帶來顯著的協同效應,利用收購業務的互補優勢,推動集團的品牌中藥組合的拓展。此舉符合集團收購資產及業務的策略,具有良好的戰略契合度,有助強化其長遠願景及提升股東價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.